RECURRENT UROTHELIAL CARCINOMA
Clinical trials for RECURRENT UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to attack tough bladder cancer
Disease control OngoingThis early-phase trial is testing the safety and best dose of a two-drug combination for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The study is for patients whose cancer has continued to grow despite trying standard chemothera…
Matched conditions: RECURRENT UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: RECURRENT UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: RECURRENT UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC